Boston Scientific Corporation
BSX
$102.86
-$0.43-0.42%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 19.08% | 20.68% | 44.31% | -34.34% | -1.98% |
| Total Depreciation and Amortization | -6.61% | 13.73% | -1.61% | 2.30% | -2.88% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 0.92% | 257.38% | -84.20% | 257.41% | -44.90% |
| Change in Net Operating Assets | -309.26% | 95.18% | 179.43% | 71.87% | -1,203.51% |
| Cash from Operations | -62.84% | 45.31% | 23.25% | 395.73% | -82.86% |
| Capital Expenditure | 32.49% | -54.75% | -15.48% | 13.41% | 32.96% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 93.01% | -203.28% | -2,247.92% | -2.13% | 94.07% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -572.73% | 90.91% | -77.94% | -15.25% | -942.86% |
| Cash from Investing | 86.50% | -159.57% | -426.57% | 4.91% | 72.93% |
| Total Debt Issued | 724.34% | 759.09% | -- | -100.00% | -- |
| Total Debt Repaid | -- | -- | -- | 100.00% | -- |
| Issuance of Common Stock | 310.71% | -70.83% | 269.23% | -67.50% | 370.59% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -253.57% | 175.68% | -5,450.00% | 98.43% | -335.19% |
| Cash from Financing | 8.88% | 2,957.14% | -70.83% | -98.47% | 10,360.00% |
| Foreign Exchange rate Adjustments | 533.33% | -250.00% | 700.00% | 85.71% | -275.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 115.31% | -396.12% | -172.92% | -60.79% | 1,971.43% |